Literature DB >> 1899470

Recognition of gonadotroph adenomas in women.

L Daneshdoost1, T A Gennarelli, H M Bashey, P J Savino, R C Sergott, T M Bosley, P J Snyder.   

Abstract

BACKGROUND: Pituitary adenomas that arise from the gonadotroph cells are being recognized with increasing frequency in men, but they are still rarely recognized in women. This rarity could be the result of an actual difference in occurrence or of greater difficulty in recognition. The tumors are usually recognized in men more than 50 years old, but elevated serum gonadotropin levels in women of that age could be produced by normal gonadotroph cells.
METHODS: Because the stimulation of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and the beta subunit of LH (LH beta) by thyrotropin-releasing hormone (TRH) is a characteristic of gonadotroph adenomas in men, we administered TRH to 16 women with apparently nonsecreting pituitary macroadenomas and measured serum FSH, LH, LH beta, and the glycoprotein hormone alpha subunit every 15 minutes for 90 minutes before and 90 minutes after. The results were compared with the responses in 16 healthy women matched for age and in 10 women with macroadenomas secreting prolactin, growth hormone, or corticotropin. The tumors from 12 of the women with nonsecreting adenomas were cultured, and the secretion of FSH, LH, and LH beta in culture was determined.
RESULTS: Eleven of the 16 women with apparently nonsecreting adenomas had significant increases in serum LH beta in response to TRH, 3 had FSH responses, and 4 had LH responses. None of the 16 healthy women and none of the 10 women with secreting macroadenomas had LH beta, FSH, or LH responses to TRH. Ten of the 12 adenomas that were cultured secreted readily detectable amounts of FSH, LH, and LH beta, and their secretion in vitro correlated with the patients' responses to TRH in vivo.
CONCLUSIONS: Most apparently nonsecreting pituitary macroadenomas in women arise from gonadotroph cells. The majority of these can be recognized, even in postmenopausal women, by the serum LH beta responses to TRH, and some can be recognized by the responses of serum FSH and LH.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899470     DOI: 10.1056/NEJM199102283240904

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  15 in total

1.  The silent corticotropinoma: is clinical diagnosis possible?

Authors:  B Ambrosi; P Colombo; D Bochicchio; M Bassetti; B Masini; G Faglia
Journal:  J Endocrinol Invest       Date:  1992-06       Impact factor: 4.256

Review 2.  Functional Gonadotroph Adenomas: Case Series and Report of Literature.

Authors:  David J Cote; Timothy R Smith; Courtney N Sandler; Tina Gupta; Tejus A Bale; Wenya Linda Bi; Ian F Dunn; Umberto De Girolami; Whitney W Woodmansee; Ursula B Kaiser; Edward R Laws
Journal:  Neurosurgery       Date:  2016-12       Impact factor: 4.654

3.  Microsurgical management of giant pituitary tumors.

Authors:  W A King; G E Rodts; D P Becker; D Q Mc Bride
Journal:  Skull Base Surg       Date:  1996

Review 4.  The evaluation and management of subclinical pituitary disease.

Authors:  S G Soule; H S Jacobs
Journal:  Postgrad Med J       Date:  1996-05       Impact factor: 2.401

Review 5.  Silent (clinically nonfunctioning) pituitary adenomas.

Authors:  Sarah E Mayson; Peter J Snyder
Journal:  J Neurooncol       Date:  2014-03-28       Impact factor: 4.130

6.  Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer.

Authors:  Y Reznik; F Chapon; N Lahlou; N Deboucher; J Mahoudeau
Journal:  J Endocrinol Invest       Date:  1997-10       Impact factor: 4.256

7.  Gonadotrophin and free alpha-subunit secretion in patients with acromegaly and clinically non-functioning pituitary tumors: anterior pituitary function and the effect of thyrotrophin-releasing hormone.

Authors:  S S Damjanović; V P Popović; M S Petakov; M M Nikolic-Durović; M Z Doknić; M S Gligorović
Journal:  J Endocrinol Invest       Date:  1996-11       Impact factor: 4.256

Review 8.  Pituitary tumor diagnosis and treatment.

Authors:  Paul L Penar; David J Nathan; Muriel H Nathan; Afshin Salsali
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

9.  Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline.

Authors:  T Lohmann; C Trantakis; M Biesold; S Prothmann; S Guenzel; R Schober; R Paschke
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

10.  Serum FSH bioactivity and inhibin levels in patients with gonadotropin secreting and nonfunctioning pituitary adenomas.

Authors:  S Borgato; L Persani; R Romoli; D Cortelazzi; A Spada; P Beck-Peccoz
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.